IGM Biosciences, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: IGM Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2024.
IGM Biosciences, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 155 %, a 80.1% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	155	+68.8	+80.1%	Sep 30, 2024
Q2 2024	117	+38	+47.8%	Jun 30, 2024
Q1 2024	100	+29.4	+41.7%	Mar 31, 2024
Q4 2023	92.8	+34.3	+58.6%	Dec 31, 2023
Q3 2023	85.9	+40.2	+88.2%	Sep 30, 2023
Q2 2023	79.4	+47	+145%	Jun 30, 2023
Q1 2023	70.6	+53.5	+312%	Mar 31, 2023
Q4 2022	58.5	+45.8	+362%	Dec 31, 2022
Q3 2022	45.6	+36.2	+385%	Sep 30, 2022
Q2 2022	32.4	+24.1	+291%	Jun 30, 2022
Q1 2022	17.2	+8.55	+99.5%	Mar 31, 2022
Q4 2021	12.7	+3.5	+38.2%	Dec 31, 2021
Q3 2021	9.41	-0.59	-5.9%	Sep 30, 2021
Q2 2021	8.29	-0.09	-1.07%	Jun 30, 2021
Q1 2021	8.59			Mar 31, 2021
Q4 2020	9.15			Dec 31, 2020
Q3 2020	10			Sep 30, 2020
Q2 2020	8.38			Jun 30, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.